A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

Completed

Conditions studied: Rheumatoid Arthritis, Psoriatic Arthritis

In brief

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Key facts

Study ID

NCT05413044

Run by

Bristol-Myers Squibb

People needed

140706

Starts

2019-07-01

Expected to finish

2025-10-31

Last updated by the study team

2025-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of RA or PsA
• ≥18 years at index treatment initiation
• Participants starting treatment with:
• abatacept
• non-targeted DMARDs
• targeted DMARD

You may not qualify if…

• Not applicable

Where it is running

• Local Institution — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.